RGLS - יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Regulus Therapeutics
Investing in Regulus Therapeutics (RGLS) carries high risks due to a lack of sales and a dependence on scientific research outcomes, which often necessitates new equity offerings. This EV/EBITDA chart, where the value is , clearly illustrates price changes and underscores the link between financial stability and the development of RNA therapies for kidney disease. However, positive Phase 1 trial results and patent protection establish a solid foundation for expansion.
פילוחים אנליטיים של חברת regulusrx.com (RGLS)
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profitability to determine the company's resilience to debt load. By analyzing fluctuations in the EV/EBITDA level, an investor assesses the asset's ability to service obligations amidst revenue volatility. For Regulus Therapeutics (RGLS), this calculation is critical, as the dependence on microRNA drug approvals and R&D expenditures makes cash reserves the determining factor for survival.
